/ People /
OUR TEAM
-
GIL GURFINKELManaging Partner -
DR. YAEL GRUENBAUM-COHENGeneral Manager -
DR. GOOZY HARTOGDirector -
DR. MATAN OFIRDirector -
Dr. Maria Jessa JablonskaManager -
DR. ASSI TSURPortfolio Manager -
Dr. Itsik FrancisManager -
Dr. Inna GrodzovskiSenior Analyst -
Dr. Yoav BaumanAnalyst -
Dr. Shiri RonAnalyst -
Dr. Michael SantosuossoAnalyst -
Dr. Ahuvit DavidAnalyst -
Dr. Niv MazkerethAnalyst -
TAMAR SHAPIRAAdministration
GIL GURFINKEL
Managing Partner
As Managing Partner of Medison Ventures and as VP of Corporate development for the Medison Group, Gil applies his vast experience in business strategy, consulting, corporate finance, private equity and capital markets, gained from his time as Vice President of Shamrock, a private equity fund, and as board member of several Israeli and international companies. Gil holds an MBA from the Recanati Business School at Tel Aviv University and a BSc from the Technion.
DR. YAEL GRUENBAUM-COHEN
General Manager
Prior to joining Medison Ventures Yael spent four years as Medical Manager of Medison’s Rare Disease Division, where she supported over 17 products and pre-launched seven. Yael completed her DMD and Ph.D. at the Hebrew University where she studied mesenchymal stem cells migration before joining as postdoctoral fellow to the Weizmann Institute of Science to investigate the underlying molecular genetics of muscle stem cell fusion.
DR. GOOZY HARTOG
Director
Goozy brings to his role in Medison Ventures experience gained as a Consultant with the Boston Consulting Group, where he consulted on multiple pharma projects for multinational companies. Prior to that Goozy worked with the Solution Lab to support early stage biotech and medical device companies. Goozy completed his Ph.D. in neurobiology at the New York Medical College where he studied the underlying biology of posttraumatic stress disorder.
DR. MATAN OFIR
Director
Prior to joining Medison Ventures Matan was part of the business development team of Cold Genesys, a US-based clinical stage biotech company. Matan holds a Ph.D. in biology from Bar-Ilan University where he studied transcription mechanisms and later he completed a postdoctoral fellowship looking at the role of long non-coding RNAs in the innate immune response at City of Hope National Medical Center in California. Matan also holds a Post-doctoral Professional Masters in Bioscience Management from the Keck Graduate Institute.
Dr. Maria Jessa Jablonska
Manager
Before joining Medison Ventures, Maria worked as a market access lead in CEE Region at AveXis, dedicated to developing and commercializing gene therapies for patients devastated by rare and life-threatening neurological genetic diseases. She also held country and global medical and market access roles in Ipsen and Sanofi. Physician by education, Maria obtained a Ph.D. in neuropsychopharmacology from the Warsaw Medical University and a postdoctoral fellowship from Lundbeck, Copenhagen, in the field of preclinical anxiety and depression research.
DR. ASSI TSUR
Portfolio Manager
Assi is the Portfolio Manager of Medison’s healthcare-focused hedge fund. Before joining Medison, Assi was an equity analyst at Nexthera Capital, a New-York based biotech-focused Hedge Fund. Prior to that, Assi served as a Biotech Consultant at L1 Capital, New York, and as a Biotech Analyst at Natalitix. Assi holds a Ph.D. from Tel Aviv University where he studied the role of the SUMO pathway in epidermal morphogenesis.
Dr. Itsik Francis
Manager
Itsik brings to Medison Ventures an extensive knowledge gained as a director at Ariel University’s tech transfer office. During his role at Ariel, Itsik performed technology scouting, commercialization, and raised funding from the Israel Innovation Authority. Prior to Ariel, Itsik worked as an Ass. Research Scientist at Columbia University, working on a variety of drug development projects. Itsik holds a Ph.D. from University College London where he studied epigenetic mechanisms in Alzheimer’s Disease.
Dr. Inna Grodzovski
Senior Analyst
Before joining Medison Ventures, Inna worked as a client strategist at the FreeMind group, a life-science non-dilutive funding consultancy firm, assisting biotech companies and academic groups to secure non-dilutive funding from US federal agencies like NIH, DOD and private foundations. Inna holds a Ph.D. in cellular and molecular biochemistry focusing on chimeric protein targeted cancer therapy from the Hebrew university and a postdoctoral fellowship from Mount Sinai, in the field of transplant tolerance.
Dr. Yoav Bauman
Analyst
Prior to joining Medison Ventures, Yoav was the co-founder and CEO of two start-up companies that developed licensing platforms for life-sciences technologies and scouting.
Yoav holds a Ph.D. in biology from the Hebrew University in the fields of immunology and cancer research.
Dr. Shiri Ron
Analyst
Prior to joining Medison, Shiri was the Senior Scientist at several biotech companies developing digital health solutions for Mental health disorders and was a Scientific Consultant at the Weizmann Institute of Science. She also served as Scientific Editor at Vikki Academy; a company focused on building bidirectional connections between academia and relevant stakeholders. Shiri holds a Ph.D. in Neurobiology from the Weizmann Institute, where she developed a novel method for decoding real-time neuronal activity from genetically defined populations in the brain.
Dr. Michael Santosuosso
Analyst
Prior to joining Medison Ventures, Michael worked as a Senior MSL at Sunovion Pharmaceuticals Canada in Infectious Diseases. He has also held Medical Affairs roles at Biogen Canada and Janssen Canada, working in diverse therapeutic areas such as, neurology and autoimmune diseases. Michael obtained his PhD in molecular immunology from McMaster University, Hamilton, Ontario Canada and earned his postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital.
Dr. Ahuvit David
Analyst
Prior to joining Medison Ventures, Ahuvit worked as a senior scientist at the FutuRx biotech incubator accelerator program focusing on future drug-discovery research. Ahuvit completed her Ph.D. in cell and developmental biology at the Sheba Cancer Research Center where she studied centrosome physiology during embryogenesis and a postdoctoral fellowship in the Netherlands Cancer Institute and TAU, looking at the non-coding genome regulating mammalian eye development.
Dr. Niv Mazkereth
Analyst
Niv joined Medison Ventures following his role as a Medical Affairs Manager at Medison Pharma, where he worked in the solid tumor oncology therapeutic area, focusing mainly on renal cell carcinoma, hepatocellular carcinoma, melanoma and non-small cell lung cancer.
Prior to joining Medison, Niv completed his Ph.D. studies at Tel-Aviv University, in the Medical sciences field, studying cancer and immunology by implementation of high-end imaging techniques, collaborating with the Laser-Laboratorium Göttingen e.V. in Germany. Throughout his years in the academy, Niv held several academic instructor positions, tutoring B.Sc. and MS.C. students within the life-sciences and medical-sciences faculties, in several courses.
TAMAR SHAPIRA
Administration
Tamar supports all aspects of coordination and logistics. Prior to joining Medison Ventures, Tami worked at Janssen Pharmaceutical as a Compliance Assistant. Tami holds a M.Sc in Biotechnology from the Hebrew University and a B.A in Biology from Bar Ilan University.